INOVA Diagnostics, Inc., provider of autoimmune diagnostic reagents and systems, has announced the global launch of QUANTA Lite Calprotectin, a new FDA-cleared assay. This assay aids in the diagnosis of Inflammatory Bowel Disease (IBD), and can also help differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other laboratory and clinical findings.
The accurate detection of calprotectin levels in stool can provide critical information to physicians determining appropriate care for patients suffering from gastrointestinal disorders. QUANTA Lite Calprotectin is an FDA-cleared, quantitative enzyme linked immunosorbent assay (ELISA) that detects calprotectin levels.
“Inaccurate diagnosis of gastrointestinal pain at the screening level can contribute to unnecessary procedures and increased healthcare costs,” says Michael Mahler, PhD, Vice President of Research and Development for INOVA Diagnostics. “The QUANTA Lite Calprotectin assay can improve patient care while potentially reducing overall costs.”
Roger Inglès, CEO of INOVA Diagnostics, adds, “The benefits of fecal calprotectin testing are being recognized by healthcare systems around the world, as evidenced by the recent recommendation from the National Institute for Health and Care Excellence (NICE) in the UK. INOVA Diagnostics is positioned to quickly increase awareness and adoption of this important new test across the globe.“
A recent recommendation from NICE has confirmed the benefits of fecal calprotectin testing and increased awareness of its importance to healthcare systems around the world. “Looking at the available evidence, we found that fecal calprotectin testing is a good way to distinguish between IBD and IBS,” says Carole Longson, PhD, Director of the Centre for Health Technology Evaluation at NICE. “It will reduce both the time spent searching for a diagnosis and the numbers of invasive procedures such as colonoscopy.” Learn more about the QUANTA Lite Calprotectin assay.
Read more
